Gene chip screening was used to define the possible downstream pathways of UNC13B. Western blot was performed to further validate the possible genes mediated by UNC13B for arsenic trioxide resistance in patients with chronic myeloid leukemia. The gene discussed is UNC13B; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.